Estuary Biotherapeutics
Estuary Biotherapeutics develops locally delivered gene therapies for patients with inherited polycystic kidney disease.
$93MSeries A
ParticipantGG
GV (Google Ventures)
Activity from announced rounds
Activity in this selectionOct 24, 2026 · Biotech · Jan 1, 2026
GV invests in technology and life-science companies, including AI applications, developer tools, cybersecurity, computing infrastructure and healthcare.
Its AI interests span the stack: new computing systems and inference infrastructure, tools for developers, software for professional workflows and applications in drug discovery and patient care. This gives both infrastructure founders and application builders a route to a specialist investment team.
GV developed the design sprint, a five-day process that takes a business question through problem definition, prototyping and customer testing. Its published sprint materials help teams test demand and product decisions before committing to a full launch.
- Rounds participated in
- 10
- Confirmed lead rounds
- 1 7 roles undisclosed
- New companies
- 10 First participation on record · 0 follow-on
- Funding in participating rounds
- $3.6B 10 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
10 in this selectionOMass Therapeutics
OMass Therapeutics develops small-molecule medicines for endocrine and immune diseases using a platform that measures drug targets in their biological surroundings.
$310MSeries C
ParticipantEncoded Therapeutics Inc.
Encoded develops precision gene therapies for neurological disorders, led by ETX101, a gene-regulation therapy for people with SCN1A-positive Dravet syndrome.
$275MSeries F
LeadLifeMine Therapeutics
Develops fungal genome-derived therapeutics for organ transplant rejection
$263MSeries D+Series E
Role not disclosedContraline
Develops hormonal and non-hormonal male contraceptives for men and couples globally
$92.5MSeries B
Role not disclosedIsomorphic Labs
Builds an AI-first drug design engine to accelerate discovery and development across multiple therapeutic areas
$2.1BSeries B
Role not disclosedIterative Health
Develops technology and services for clinical research.
$77MSeries C
Role not disclosedEpiBiologics
Develops bispecific antibodies for targeted degradation of extracellular proteins.
$107MSeries B
Role not disclosedParabilis Medicines
Develops medicines targeting historically undruggable protein targets in cancer
$305MSeries F
Role not disclosedPrudentia Sciences
Provides AI-native due diligence for life sciences dealmaking
$20MSeries A
Role not disclosed